Ovarian function is preserved in women with severe systemic lupus erythematosus after a 6-month course of cyclophosphamide followed by mycophenolate mofetil

Clinical and Experimental Rheumatology

Volumn 28, Issue 1, 2010, Pages 83-86

  Laskari, Katerina ^a   Zintzaras, Elias ^b   Tzioufas, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

Author keywords

Amenorrhea; Mycophenolate mofetil; Severe lupus; Short course cyclophosphamide treatment

Indexed keywords

CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RO ANTIBODY;

ADULT; AMENORRHEA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; GONAD FUNCTION; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; OVARY FUNCTION; PREMENOPAUSE; PRIORITY JOURNAL; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SUSTAINED AMENORRHEA; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION;

ADOLESCENT; ADULT; AMENORRHEA; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; MYCOPHENOLIC ACID; OVARIAN FUNCTION TESTS; OVARY; PREMENOPAUSE; PULSE THERAPY, DRUG; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 77949508210     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. CONTRERAS G, PARDO V, LECLERCQ B et al.: Sequential Therapies for Proliferative Lupus Nephritis. N Engl J Med 2004; 350: 971-80.
2. ILLEI GG, AUSTIN HA, CRANE M et al.: Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis. Ann Intern Med 2001; 135: 248-57.
3. HOUSSIAU FA, VASCONCELOS C, D'CRUZ D et al.: Immunosuppressive therapy in lupus nephritis. The Euro-Lupus Nephritis trial, a randomized trial of low-dose versus high dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-31.
4. PARK J-C, PARK Y-B, JUNG SY, CHUNG IH, CHOI KH, LEE S-K: Risk of Ovarian Failure and Pregnancy Outcome in Patients With Lupus Nephritis Treated With Intavenous Cyclophosphamide Pulse Therapy. Obstet Gynecol Surv 2005; 60: 148-50.
5. IOANNIDIS JPA, KATSIFIS GE, TZIOUFAS AG, MOUTSOPOULOS H: Predictors of Sustained Amenorrhea from Pulsed Intravenous Cyclophosphamide in Premenopausal Women with Systemic Lupus Erythematosus. J Rheumatol 2002; 29: 2129-35.
6. BOUMPAS DT, AUSTIN HA, VAUGHAN EM, YARBORO CH, KLIPPEL JH, BALOW JE: Risk for Sustained Amenorrhea in Patients with Systemic Lupus Erythematosus Receiving Intermittent Pulse Cyclophosphamide Therapy. Ann Intern Med 1993; 119: 366-9.
7. MOK CC, LAU CS, WONG RW: Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy: Arthritis Rheum 1998; 41:831-7.
8. HUONG DL, AMOURA Z, DUHAUT P et al.: Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol 2002; 29: 2571-6.
9. KATSIFIS GE, TZIOUFAS AG: Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus 2004; 13: 673-8.
10. CHAN TM, LI FK, TANG CS et al.: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156-62.
11. TAN EM, COHEN AS, FRIES JF et al.: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
12. WEENING JJ, D'AGATI VD, SCHWARTZ MM et al.: Classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-50.
13. RENAL DISEASE SUBCOMMITTEE of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria: The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006; 54: 421-32.
14. MCDERMOTT EM, POWELL R: Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide: Ann Rheum Dis 1996; 55: 224-9.
15. SHABANOVA SS, ANANIEVA LP, ALEKBEROVA ZS, GUZOV II: Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin Exp Rheumatol 2008; 26: 436-41.
16. SOMERS EC, MARDER W, CHRISTMAN GM, OGNENOVSKI V, MCCUNE WJ: Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus: Arthritis Rheum 2005; 52: 2761-7.